We are live on ! Find out more
XRTX

XORTX Therapeutics
XRTX

5 hedge funds and large institutions have $81.5K invested in XORTX Therapeutics in 2025 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

35% more capital invested

Capital invested by funds: $60.2K → $81.5K (+$21.3K)

0.96% more ownership

Funds ownership: 1.71% → 2.67% (+0.96%)

17% less funds holding

Funds holding: 6 → 5 (-1)

50% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 2

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

Holders
5
Holders Change
-1
Holders Change %
-16.67%
% of All Funds
0.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
1
Reduced
2
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$40.1K
2
XT
XTX Topco
Cayman Islands
+$11.6K

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$17.2K
2
National Bank of Canada
National Bank of Canada
Quebec, Canada
-$3.9K
3
Raymond James Financial
Raymond James Financial
Florida
-$453
4
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
-$256

XRTX Hedge Fund Activity: Q3 2025 in Review

5 of the 7,641 institutional investors tracked by Wall St. Rank reported a position in XORTX Therapeutics (XRTX) for Q3 2025, worth a combined $81.5K — up 35% from $60.2K a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of XRTX and 1 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 1 added.

The largest buyer was Citadel Advisors, adding an estimated $40.1K. The largest seller was UBS Group, cutting an estimated $17.2K.

  • 5 institutional investors held XORTX Therapeutics (XRTX) as of Q3 2025, down from 6 in Q2 2025.
  • Funds reported $81.5K of XORTX Therapeutics stock for Q3 2025, up 35% quarter-over-quarter.
  • 1 fund opened new XORTX Therapeutics positions in Q3 2025 and 2 closed out, a net change of -1 holder.
  • The largest XORTX Therapeutics buyer in Q3 2025 was Citadel Advisors, an estimated $40.1K added.
  • The largest XORTX Therapeutics seller in Q3 2025 was UBS Group, an estimated $17.2K sold.

Based on aggregated 13F filings for Q3 2025.